Abstract
The promyelocytic zinc finger transcription factor (PLZF) is required for the development of activated phenotypes in NKT and other innate T lymphocytes. Although strong TCR stimulation has been implicated in the induction of PLZF, the factors regulating PLZF expression are incompletely understood. We show in this study that costimulation of preselection double-positive thymocytes through the signaling lymphocyte activation molecule family receptor Ly108 markedly enhanced PLZF expression compared with that induced by TCR stimulation alone. Costimulation with Ly108 increased expression of early growth response protein (Egr)–2 and binding of Egr-2 to the promoter of Zbtb16, which encodes PLZF, and resulted in PLZF levels similar to those seen in NKT cells. In contrast, costimulation with anti-CD28 failed to enhance Egr-2 binding and Zbtb16 expression. Moreover, mice lacking Ly108 showed decreased numbers of PLZF-expressing CD4+ T cells. Together, these results support a potential role for Ly108 in the induction of PLZF.
Introduction
Innate-like T cells, including NKT cells, differ from their conventional counterparts in that they possess innate, memory-like, rather than naive phenotypes upon maturation, and rapidly secrete effector cytokines upon activation without need for prior differentiation. As such, innate-like T cells play an important role at the interface between the innate and adaptive immune systems (1).
Recent data demonstrate that the promyelocytic zinc finger transcription factor (PLZF) is required for the acquisition of activated phenotypes by invariant NKT (iNKT) and other innate-like T lymphocytes. Whereas ectopic expression of PLZF is sufficient to impart an activated phenotype to conventional T cells, its absence can impair both the expansion and effector differentiation of iNKT cells (2–6). Therefore, PLZF most likely plays a critical role in setting the tone of immediate lymphocyte responses. However, the factors regulating PLZF expression are only minimally understood. Whereas data suggest that strong TCR signals associated with high expression of the Ras- and Ca2+-dependent early growth response transcription factors early growth response protein (Egr)–1 and –2 lead to PLZF induction (4, 7), it is not clear that PLZF expression is governed solely by signals from the TCR (8). Unlike conventional αβ TCR+ cells, iNKT and other innate-like T cells undergo a distinct pathway of selection that requires interactions with and selection on MHC and related molecules expressed on other double-positive (DP) thymocytes instead of thymic stroma, suggesting that distinct signaling pathways may be activated during their development (9). Indeed, PLZF can be induced in developing thymocytes by enforced T cell–T cell interactions (10, 11). These data suggest that PLZF expression may be regulated in part by receptor/ligands expressed specifically on DP cells rather than on thymic stroma.
Of interest in this regard are the signaling lymphocyte activation molecule (SLAM) family receptors, which are expressed at high levels on DP thymocytes, but are absent from the thymic stroma (12). Mutations affecting the SLAM-associated protein (SAP), which is required for signaling downstream of SLAM family receptors (13), result in a drastic loss of iNKT and other innate T lymphocytes (14–19). Studies using mixed bone marrow chimeras have further implicated two SLAM members, SLAM and Ly108, in the development of iNKT cells (12). Nonetheless, how these receptors contribute to the development of iNKT and other innate T cell lineages is not well understood.
We have recently found that the homophilic SLAM family receptor Ly108 (CD352, encoded by Slamf6) is heavily phosphorylated in the thymus in a contact-dependent manner (20). Given the connection between Ly108 and innate T cells, we examined the effects of Ly108 on the expression of PLZF and other transcription factors required for innate T lymphocyte development. We find that Ly108 engagement amplifies TCR signaling, prolonging phosphorylation of linker of activated T cells (LAT), phospholipase C (PLC)–γ, and ERK and increasing expression of Egr-2. Strikingly, costimulation with Ly108, but not CD28, led to a dramatic induction of PLZF associated with increased Egr-2 binding to the promoter of Zbtb16, the gene encoding PLZF. Moreover, Ly108-deficient mice have decreased numbers of PLZF+CD4+ cells, and, conversely, a mouse model with enhanced Ly108 signaling (B6.Sle1b) showed increased numbers of PLZF+CD4+ cells. Our results suggest that Ly108 contributes a distinct signal that can potentiate TCR-mediated induction of PLZF.
Materials and Methods
Mice
Mice were used in accordance with the Institutional Animal Care and Use Committee, National Human Genome Research Institute, National Institutes of Health. Sh2d1a−/− (21) mice were backcrossed to C57BL/6J for 10 generations and carry the C57BL/6J-derived SLAM locus. C57BL/6J were from The Jackson Laboratory. MHC class I/class II–deficient (B6.129-H2-Ab1tm1Gru B2mtm1Jae) (22) and β2m−/− (B2mtm1Jae) (23) mice were from Taconic. Egr1−/−Egr2fl/fl/LckCre mice were previously described (24–26). Slamf6−/− mice (Supplemental Fig. 2) were generated by introducing a stop codon into exon 2 and removing part of exons 2 and 3 of Slamf6 in HGTC-8 C57BL/6J-derived embryonic stem cells (27). B6.Sle1b mice have been previously described (28).
Preselection DP cell isolation
Preselection DP (PS-DP) thymocytes were isolated by negative selection (anti-FITC isolation kit; Miltenyi Biotec) using FITC-CD3, CD25, and CD44 Abs, which removed postselection cells (CD3high), CD25+ double-negative (DN) cells, as well as mature (CD44high) innate T cells (eBiosciences). Postselection, cells were ≥98% CD4+CD8+ and ≥99% CD69low and CD44low. Additionally, >98% of PLZF+ cells were removed by this treatment (Supplemental Fig. 1). In some experiments, anti-γδTCR was also included in the negative selection step to deplete γδ T cells. Both selection procedures gave comparable results.
Cell culture and staining
A total of 5 × 106 PS-DP thymocytes was stimulated in 0.5 ml complete RPMI 1640 plus 8% FBS, 1% pen/strep, 2 mM l
Real-time PCR
RNA was isolated with TRIzol and the RNeasy mini kit (Qiagen). cDNA was generated by TaqMan reverse-transcription reagents (Applied Biosystems). cDNA was amplified with TaqMan probe primer mixes (Applied Biosystems).
Chromatin immunoprecipitations
PS-DP thymocytes were harvested 18 h poststimulation, and chromatin immunoprecipitations (ChIPs) were performed using Magna ChIP-A kit (Millipore). DNA was sheared in 500 μl using a Misonix 3000 water bath sonicator (Output 5.5, 6 min 30 s on, 30 s off), and 50 μl (1 × 106 cell equivalent) sheared DNA was immunoprecipitated and sequences were amplified by SYBR Green quantitative PCR with the following primers: Egr-2 forward, 5′-ATCCGGAGCAACAGTTCCCC-3′; Egr-2 reverse, 5′-TGGGCGGTGCGAGTCCTTC-3′; CREB forward, 5′-AGCACTAAAGATGGAGAGGCG-3′; CREB reverse, 5′-TCGCAGTACCCGCTCTCG-3′; NFAT forward, 5′-TTCTGACTCTGAGTTTGGGGATAAATGAC-3′; NFAT reverse, 5′-TGGGTTTGCTAGTTATTAGTCAGAGATG-3′. ChIPs were normalized to input DNA and expressed as fold enrichment relative to isotype control from nonstimulated (NS) thymocytes.
Stimulations and protein analyses
Thymocytes were incubated with biotinylated anti-CD3ε, anti-CD4 (Becton Dickinson Biosciences) ± anti-Ly108 (eBiociences); washed; stimulated with streptavidin; and stopped with 2× SDS loading buffer. Immunoblots were probed with 4G10, LAT, and PLCγ-1 (Millipore); phospho-LAT Y191 and phospho-PLCγ-1 Y783 (BioSource International-Invitrogen); phospho–protein kinase C (PKC)θ Thr538, phospho-ERK, and ERK (Cell Signaling); and PKCθ (Santa Cruz Biotechnology), followed by TrueBlot HRP-secondary Ab. For analysis of Ly108 phosphorylation in intact B6 and B6.Sle1b thymi, freshly harvested intact thymi were crushed in radioimmunoprecipitation assay lysis buffer and Ly108 immunoprecipitated from cleared lysates for 2 h at 4°C using anti-Ly108 monoclonal (13G3-19D clone; eBiosciences) and protein A agarose beads (Santa Cruz Biotechnology). Immunoprecipitates were resolved on 10% Tris glycine gels and were probed for phosphotyrosine using 4G10 and for total Ly108 protein using polyclonal Ly108 rabbit Ab (20). Western blots were developed using ECL detection reagents (GE Healthcare). Films were scanned, and intensities were quantitated using imageJ software (NIH, http://rsb.info.nih.gov/ij).
Ca2+ flux
PS-DP thymocytes were incubated with Fluo-3 and Fura-red (Molecular Probes/Invitrogen) and incubated with biotinylated anti-CD3ε and anti-CD4 ± anti-Ly108 for 30 s, at 37°C, followed by cross-linking with streptavidin. Data were collected for 10 min (FACSCalibur; Becton Dickinson Biosciences), analyzed using FlowJo (Tree Star), and plotted as the ratio of Fluo-3/Fura-red.
Statistical analysis
A two-tailed, paired Student t test was used to calculate p values.
Results
Ly108 costimulation enhances Zbtb16 induction in PS-DP thymocytes
To evaluate factors that regulate PLZF expression, we first isolated PS-DP thymocytes by negative selection using Abs to CD3, CD25, and CD44 (Supplemental Fig. 1A). This selection enriches for preselection thymocytes that have not upregulated their TCR and also depletes CD25+ DN cells as well as innate lymphocytes, which are CD44high. After purification, the isolated cells were >98% DP and >99% CD69low, CD44low. Over 98% of pre-existing PLZF+ cells were removed by this treatment (Supplemental Fig. 1A–E). As seen for developing γδ cells (4), stimulation of PS-DP thymocytes with plate-bound anti-CD3 led to an induction of Zbtb16 (Fig. 1A). However, costimulation with both anti-CD3 and an anti-Ly108 Ab capable of inducing Ly108 phosphorylation (Supplemental Fig. 1F) (20) dramatically increased Zbtb16 expression above stimulation with anti-CD3 alone (Fig. 1B). This enhancement of Zbtb16 message required stimulation of both CD3 and Ly108, as anti-Ly108 alone was unable to induce Zbtb16 expression above background.
Ly108 costimulation enhances PLZF expression in developing PS-DP thymocytes. (A) Expression of Zbtb16 (encoding PLZF) evaluated by quantitative RT-PCR (qRT-PCR) of WT PS-DP thymocytes stimulated with media alone (NS) or plate-bound anti-CD3 for 24 or 48 h. (B) Zbtb16 expression of WT PS-DP thymocytes stimulated with media alone (NS), anti-CD3 ± anti-Ly108, or anti-Ly108 alone. Values in (A) and (B) were normalized to NS WT samples. Similar results were obtained using freshly isolated PS-DP cells as normalization controls (Supplemental Fig. 2A). Data are the means ± SEM of five independent experiments, using cells from ≥3 mice each. (C) Zbtb16 expression in WT and β2-microglobulin–deficient PS-DP thymocytes stimulated with plate-bound anti-CD3 ± anti-Ly108. Data are from two independent experiments. Cells in these experiments were also negatively selected to remove TCRγδ+ cells. (D) Zbtb16 expression in WT and SAP-deficient (Sh2d1a−/−) PS-DP thymocytes in the presence or absence of Ly108Fc fusion protein was stimulated with LPS-activated B cells (which express high surface levels of Ly108) plus anti-CD3. Data are the means ± SEM of three independent experiments, using cells from ≥3 mice each. RQ, relative quantitation.
To confirm that the induction in Zbtb16 did not result from a specific outgrowth or survival advantage of pre-existing Zbtb16-expressing population, we evaluated preselection thymocytes that were isolated from β2-microglobulin–deficient mice, which lack most classical iNKT cells (29–31). These were further negatively selected with anti-TCRγδ to minimize contribution from PLZF-expressing γδ T cells. A similar induction of Zbtb16 was also seen in preselection thymocytes from these mice (Fig. 1C), consistent with the fact that we did not detect appreciable PLZF expression in freshly isolated WT PS-DP thymocytes prior to stimulation (Supplemental Figs. 1D, 2A). Furthermore, Ly108 costimulation did not induce any appreciable proliferation of PS-DP thymocytes in plate-bound stimulations (Supplemental Fig. 2B). Thus, the induction of Zbtb16 by Ly108 costimulation is unlikely to result from the expansion of Zbtb16-expressing cells that may have escaped the purification of PS-DP cells. Although anti-CD3 stimulation of DP thymocytes does induce cell death, particularly by 48 h, Ly108 costimulation did not appear to further diminish cell viability (Supplemental Fig. 2C), also suggesting that we were not enriching for a Zbtb16+ population upon Ly108 costimulation.
To determine whether the plate-bound Ly108 Ab stimulation assay could be recapitulated using the endogenous self-ligand, and to evaluate the effects of homotypic Ly108 interactions similar to those observed in vivo, we next stimulated thymocytes with LPS-activated B cells, which express high levels of Ly108 when activated (32), and induced TCR signaling with anti-CD3. Because Ly108 is a self-ligand, this stimulation allowed engagement of Ly108 on thymocytes. Costimulation by Ly108 presented by B cells induced Zbtb16 expression in WT PS-DP thymocytes, but not in those from mice deficient in SAP, which is required for Ly108 activation (Fig. 1D). Moreover, preincubation of thymocytes with a blocking Ly108-Fc fusion protein (33) prevented this induction of Zbtb16, supporting the idea that Ly108 engagement contributes to Zbtb16 expression.
Ly108 is required for full induction of PLF in vitro
To confirm that these effects were specific for Ly108, we evaluated thymocytes from mice deficient in Ly108 (Slamf6−/− mice), which we generated on a pure C57BL/6 background to eliminate potential effects of Slam gene family polymorphisms. These mice showed no expression of Ly108, as detected by immunoblotting or flow cytometry (Supplemental Fig. 2D). As previously reported in a mixed genetic background, Slamf6−/− mice showed no gross defects in conventional CD4+ and CD8+ T cell development (Fig. 2A, Table I). However, the effects of Ly108 on Zbtb16 expression were abrogated in Ly108-deficient thymocytes, as well as in thymocytes from mice deficient in SAP or Fyn, which are required for Ly108 phosphorylation (20, 34) (Fig. 2B and data not shown). Moreover, evaluation of PLZF protein, by intracellular staining, confirmed that Ly108 costimulation increased PLZF protein levels over that induced by CD3 stimulation alone in nearly the entire population of WT PS-DP cells (Fig. 2C, 2D, Supplemental Fig. 2E), reaching levels similar to those seen in iNKT cells (Fig. 2E). Thus, Ly108 costimulation strongly enhanced anti–CD3-induced PLZF expression, to levels observed in innate T cells.
Ly108 is required for full induction of PLZF in vitro. (A) Characterization of Ly108-deficient (Slamf6−/−) mice. Representative flow plots of thymocyte populations from WT and Slamf6−/− mice stained for CD4 and CD8. Frequencies and absolute numbers of thymocyte populations (n = 6) stained for DP, DN CD4+ and CD8+ cells are depicted in Table I. (B) Zbtb16 expression in WT, Slamf6−/−, and SAP-deficient (Sh2d1a−/−) thymocytes stimulated as in Fig. 1. Values were normalized to NS WT samples. Similar results were obtained using freshly isolated PS-DP cells as controls (Supplemental Fig. 2A). Data are the means ± SEM of three independent experiments, using cells from ≥3 mice each. (C) Representative histograms of intracellular PLZF staining in PS-DP thymocytes from WT and Slamf6−/− mice, NS (solid histogram) or stimulated with plate-bound anti-CD3 ± anti-Ly108 for 48 h. Staining controls are shown in Supplemental Fig. 2E. (D) Mean fluorescence intensity ± SD of PLZF from three mice per genotype. (E) Intracellular PLZF expression in PS-DP thymocytes stimulated as in (C) compared with PLZF+CD1d-PBS57 tetramer+ iNKT cells. Histograms are representative of triplicates for each condition. Data in (E) were generated with a different Ab lot than in (C).
Ly108-deficient mice have fewer PLZF-expressing cells
To evaluate whether Ly108 contributes to PLZF expression in CD4+ T cells in vivo, we evaluated PLZF-expressing thymocytes and thymic iNKT cell numbers from Ly108-deficient (Slamf6−/−) mice. As previously reported, we found that thymic iNKT cells were reduced by ∼50% in Slamf6−/− mice (12). However, both the frequency and absolute numbers of CD4+PLZF+ thymocytes were even more compromised in Slamf6−/− mice (Fig. 3A, 3B, Table I). Despite the reduction of PLZF-positive thymocytes in Slamf6−/− mice, the intensity of PLZF in the remaining iNKT cells was similar between WT and Slamf6−/− thymocytes (Fig. 3C, 3D), suggesting compensating roles for other SLAM family members or other receptors in PLZF expression.
Ly108-deficient mice have fewer PLZF+CD4+ thymocytes. Percentages (A) and absolute numbers (B) of CD1d-PBS57 tetramer+ and PLZF+, CD4+ thymocytes in WT and Slamf6−/− mice. (C and D) PLZF levels in CD1d-PBS57 tetramer+ iNKT cells from WT and Slamf6−/− mice. Data are the mean ± SD of three mice per group.
Increased PLZF-expressing cells in a mouse model of enhanced Ly108 signaling
B6.Sle1b congenic mice carry the SLAM gene locus of lupus-prone NZM2410 mice introgressed into C57BL/6 background, and develop high levels of autoantibodies with age (28). This phenotype has been linked to higher expression of the Ly108-1 isoform, which is more heavily phosphorylated upon engagement (20, 28, 34). Consistent with these observations, we have found that lysates from intact thymi from B6.Sle1b mice show increased phosphorylation of Ly108 (Fig. 4A). Using plate-bound αCD3 ± anti-Ly108 stimulation, we further found that B6.Sle1b PS-DP thymocytes showed higher levels of Zbtb16 induction upon Ly108 costimulation compared with C57BL/6 controls (Fig. 4B). Additionally, ex vivo staining of B6.Sle1b thymocytes also revealed increased percentages and numbers of PLZF-positive cells compared with C57BL/6 controls (Fig. 4C, 4D, Table I). Taken together, our results suggest that Ly108 signaling is a potent positive regulator of PLZF-expressing cells.
Increased PLZF-expressing cells observed in a mouse model with enhanced Ly108 signaling. (A) Enhanced phosphorylation of Ly108 in intact thymi of B6.Sle1b mice. Ly108 was immunoprecipitated from lysates of intact thymi of C57BL/6J (B6) and B6.Sle1b mice and probed for phosphotyrosine using 4G10 Ab (top) and for total Ly108 protein (bottom). Quantitation of relative tyrosine phosphorylation is shown on the right. (B) Zbtb16 expression in C57BL/6J (B6) and B6.Sle1b PS-DP thymocytes stimulated for 48 h with plate-bound anti-CD3 ± anti-Ly108 as in Fig. 1. Data are representative of three independent experiments. Percentages (C) and absolute numbers (D) of PLZF+ CD4+ thymocytes in C57BL/6J (B6) and B6.Sle1b mice.
Ly108 costimulation potentiates TCR signaling
The observation that the effect of Ly108 on PLZF expression requires stimulation with anti-CD3 suggests that Ly108 functions as a costimulatory molecule to potentiate TCR signaling. To evaluate whether Ly108 affects TCR signaling, we compared tyrosine-phosphorylated proteins from thymocytes stimulated with anti-CD3 (or anti-CD3 + anti-CD4) ± anti-Ly108. Ly108 stimulation alone elicited minor changes in tyrosine phosphorylation. However, anti-Ly108 plus anti-CD3 (or anti-CD3/CD4) prolonged the tyrosine phosphorylation of multiple proteins, including a ∼37-kDa protein corresponding to the m.w. of LAT, in WT, but not Slamf6−/− thymocytes, compared with anti-CD3 (or anti-CD3/CD4) stimulation alone (Fig. 5A, Supplemental Fig. 3A). Although subtle, these effects were confirmed by probing for specific phospho-proteins, including LAT (Y191), PLCγ-1 (Y783), PKCθ (Thr538), and ERK (Fig. 5B, Supplemental Fig. 3B). To confirm that this increased signaling occurred in preselection thymocytes, we also evaluated the effects of Ly108 costimulation on thymocytes from MHC class I/class II–deficient mice that lack mature conventional single-positive (SP) thymocytes. We observed a similar prolongation of phosphorylation of signaling proteins downstream of TCR upon Ly108 costimulation (Supplemental Fig. 3C). Evidence of prolonged signaling was also observed as a stronger resurgence of ERK phosphorylation after 1 h of Ly108 costimulation (Fig. 5C).
Ly108 costimulation prolongs TCR signaling. (A) Rested WT and Slamf6−/− thymocytes, preincubated with biotinylated anti-Ly108 (top), anti-CD3 + anti-CD4 (middle), and anti-CD3 + anti-CD4 + anti-Ly108 (bottom), were stimulated with streptavidin for indicated times and lysates were immunoblotted for α-phosphotyrosine (4G10). Arrows indicate predicted migration of LAT (left). Quantitation of 37-kDa band corresponding to LAT in (A) is shown in Supplemental Fig. 3A. (B) WT thymocytes were stimulated with anti-CD3 ± anti-Ly108 as in (A), and lysates were probed for phospho-LAT (Y191), LAT; phospho-PLCγ-1 (Y783), PLCγ-1; phospho-PKCθ (Thr538), PKCθ; phospho-ERK; and ERK. Quantitation of band intensities is shown in Supplemental Fig. 3B. (C) WT thymocytes were stimulated with anti-CD3 + anti-CD4 ± anti-Ly108 for extended times and probed for phospho and total Erk proteins. (D) Ca2+ flux of WT and Slamf6−/− PS-DP thymocytes stimulated with biotin-conjugated anti-CD3/CD4 ± anti-Ly108, followed by streptavidin, as indicated by the ratio of Fluo-3/Fura-red. Arrow indicates enhanced intracellular Ca2+ levels seen in WT, but not Ly108- or SAP-deficient thymocytes, upon anti-CD3/CD4/Ly108 stimulation. (A–D) Representative of three independent experiments.
In line with increased PLCγ-1 phosphorylation, Ly108 costimulation also slightly increased the prolonged phase of Ca2+ mobilization in WT, but not Slamf6−/− PS-DP thymocytes. In contrast, Ca2+ flux was minimal with anti-Ly108 stimulation alone (Fig. 5D). Thus, although these effects are subtle, Ly108 costimulation enhanced signaling downstream of the TCR.
Egr-2 binds to PLZF promoter sequences and links Ly108 signaling to PLZF expression
The transcription factor Egr-2 is induced by TCR stimulation in a Ca2+ and NFAT-dependent manner and is important for both NKT cell development and expression of PLZF (7, 25, 35). Sequence analyses (National Center for Biotechnology Information; Mulan, http://mulan.dcode.org) revealed two conserved overlapping binding sites for Egr-2 in the Zbtb16 promoter (Fig. 6A). These sites were also found in a recent study using ChIP-Seq to evaluate potential Egr-2 binding sites, supporting a role for Egr-2 in regulating PLZF expression (7). Notably, we found that Ly108 costimulation enhanced CD3-induced Egr-2 expression in WT, but not Ly108-deficient thymocytes (Fig. 6B). This effect was detectable as early as 6 h and peaked by 12 h (Fig. 6C), preceding the increase in Zbtb16 expression (Fig. 6D). Using ChIPs, we further found that Ly108 costimulation enhanced NFATc2 binding at a conserved site upstream of Egr-2, suggesting that Ly108 costimulation increases Egr-2 expression via effects on NFATc2 (Fig. 6E).
Ly108 induces Egr-2 expression and binding to the Zbtb16 promoter. (A) Mouse and human Zbtb16 sequences, 20 kb upstream of first exon, were aligned and analyzed for conserved binding sites for Egr-2 and CREB. (B) Egr-2 expression in WT or Slamf6−/− PS-DP thymocytes stimulated as in Fig. 1B for 24 h, normalized to NS controls. Data are the mean ± SEM from six independent experiments. Egr-2 (C) or Zbtb16 (D) expression by qRT-PCR from WT and Slamf6−/− PS-DP thymocytes stimulated for 2, 6, 12, or 24 h. Time courses are representative of four independent experiments. (E–G) ChIPs from thymocytes stimulated as in Fig. 1B. (E) NFATc2 binding on the Egr-2 promoter. (F) Egr-2 binding on the Zbtb16 promoter. (G) CREB binding on the Zbtb16 promoter. ChIPs show average of two replicates ± SD from one of two or more independent experiments. (H) Zbtb16 expression in Egr-1−/−Egr-2fl/fl Lck Cre or littermate control PS-DP thymocytes stimulated as in Fig. 1B for 48 h and normalized to NS controls. (I) Egr-2 expression in C57BL/6J (B6) and B6.Sle1b PS-DP thymocytes stimulated with plate-bound anti-CD3 ± anti-Ly108 for 48 h. Data are representative of three independent experiments.
Consistent with these observations, ChIP analyses revealed that Ly108 costimulation strongly enhanced Egr-2 binding to the conserved sites within the Zbtb16 promoter in WT, but not Slamf6−/− thymocytes (Fig. 6F). In contrast, CREB, a TCR-activated transcription factor (36) that also has conserved binding sites on the Zbtb16 promoter (Fig. 6A), failed to show increased Zbtb16 binding upon Ly108 costimulation (Fig. 6G). Thus, Ly108 costimulation enhanced Egr-2 expression and binding of Egr-2 to the PLZF promoter. Consistent with a critical role for Egr proteins in the regulation of PLZF, stimulation of PS-DP thymocytes from T cell–specific Egr1−/−Egr2−/− conditional mice showed only minimal CD3-mediated induction of PLZF, which did not increase upon Ly108 costimulation (Fig. 6H). Conversely, stimulation of PS-DP thymocytes from B6.Sle1b mice that have enhanced Ly108 phosphorylation also showed increased Ly108-induced prolonged Egr-2 expression when compared with C57BL/6 controls (Fig. 6I). Taken together, our results support the hypothesis that Ly108 costimulation can increase and sustain Egr-2 expression and binding to the Zbtb16 promoter in developing thymocytes.
CD28 costimulation does not enhance PLZF expression
To test whether the enhancement of PLZF expression was specific for Ly108, we examined the effects of CD28, which also potentiates TCR signaling. To minimize CD28 costimulation-induced thymocyte death (37–39), analyses were performed after 18–24 h of stimulation (Supplemental Fig. 2C). Whereas CD28 costimulation slightly increased Egr-2 expression compared with anti-CD3 alone, it failed to increase Egr-2 expression to levels observed with Ly108 costimulation (Fig. 7A), nor did CD28 costimulation increase Egr-2 binding to the PLZF promoter (Fig. 7B). Notably, CD28 costimulation also failed to induce PLZF expression in PS-DP thymocytes (Fig. 7C). These data suggest that Ly108 provides a distinct signal that enhances PLZF expression in developing thymocytes.
CD28 costimulation does not enhance PLZF expression. (A–C) PS-DP thymocytes were stimulated with anti-CD3 ± anti-CD28 or ± anti-Ly108 and evaluated for Egr-2 expression by qRT-PCR at 18 h (A), Egr-2 binding at the Zbtb16 promoter by ChIP at 18 h (B), or Zbtb16 expression at 24 h (C). Data show the mean of two replicates ± SD from one of two or more independent experiments.
Discussion
Although SLAM family members have been implicated in iNKT and other innate T lymphocyte development, the functions of these receptors in this process have not been clear. In this work, we demonstrate that Ly108 can potentiate CD3-induced expression of Egr-2 and PLZF, a master regulator of innate T lymphocyte phenotypes. Using either plate-bound Ab or the endogenous ligand, we found that costimulation with Ly108 in vitro potently enhanced TCR-induced PLZF expression in PS-DP thymocytes, reaching levels observed in iNKT cells. Although we cannot absolutely rule out outgrowth of a previously PLZF+ population, we have rigorously purified cells to minimize PLZF+ (and iNKT) cells in our starting cultures. Moreover, as far as we can detect, Ly108 stimulation did not induce proliferation, nor did it further enhance αCD3-induced cell death, suggesting that we were not enriching for a specific PLZF-expressing population in our stimulations. Indeed, the PLZF+ cells in these cultures did not react with the CD-1d tetramer that recognizes iNKT cells.
Ly108 costimulation also increased expression of Egr-2, which is highly expressed in iNKT cells and has recently been shown to be critical for both iNKT development and PLZF expression (7, 25, 35). Supporting an important role for Ly108 in this pathway, we observed that Ly108 strongly increased Egr-2 binding to the Zbtb16 promoter and that Ly108 could not induce PLZF expression in thymocytes from mice deficient in Egr-1 and -2. Thus, although high levels of Egr-2 in iNKT cells have been interpreted as indicative of these cells having received strong TCR signals (7), our data suggest that Ly108 is also an important contributor to the induction of Egr-2, which is critical for PLZF expression. These findings were further supported by observations in B6.Sle1b mice, a model of enhanced Ly108 signaling, which show increased Egr-2 expression and increased numbers of PLZF-expressing CD4+ cells.
Although the observations that the iNKT cells that do develop in Ly108-deficient mice express normal levels of PLZF could be used to argue against a role for Ly108 in regulating PLZF expression, an alternative interpretation is that cells that successfully upregulate PLZF have a selective advantage and preferentially develop. This idea is consistent with data showing decreased iNKT cells in Zbtb16−/− animals (2, 3). Alternatively, given that bone marrow chimeras that generate a functional double deficiency in both Ly108 and SLAM have a more complete block in the development of PLZF-expressing iNKT cells (12), other SLAM family members (or other receptors) may compensate for the absence of Ly108. Consistent with this idea, we have seen that an anti-SLAM (CD150) Ab can modestly increase expression of Egr-2 and PLZF in similar plate-bound stimulation assays, although not nearly to the level seen with anti-Ly108 (data not shown). Whether this is the result of functional differences between SLAM and Ly108 or the relative efficiency of the particular stimulating Abs requires further evaluation.
It has been argued that SLAM/SAP-mediated signaling does not play a major role in the regulation of PLZF in part because of the following: 1) the defect in iNKT cell development occurs earlier in SAP-deficient than that in PLZF-deficient mice (5, 12); 2) some PLZF induction is still seen in SAP-deficient stage 0 iNKT cells (3); and 3) restoring PLZF expression by transgenic expression does not restore iNKT development in SAP-deficient mice (5). However, each of these arguments does not rule out a role for SLAM family members in the regulation of PLZF. Indeed, our results are consistent with the idea that SLAM family members affect multiple factors and stages in NKT cell differentiation, and with recent data showing that the absence of SAP leads to strong inhibitory signals that may differ from the lack of SLAM family signaling (40, 41).
Our results further suggest that the expression of PLZF can be induced in most (preselection) thymocytes that receive the appropriate signals. We have recently found that Ly108 is heavily phosphorylated in the thymus, but that phosphorylation of Ly108 is lost within minutes of dispersion of thymocytes into a single cell preparation. In contrast, anti-Ly108–mediated induction of Ly108 tyrosine phosphorylation is relatively slow compared with the global patterns of tyrosine phosphorylation induced by anti-CD3 (20). These results suggest that there is dynamic contact-mediated regulation of Ly108 phosphorylation in the thymus. Given the dramatic effects of Ly108 on PLZF induction, the rapid dephosphorylation (with relatively slow induction of phosphorylation) suggests that Ly108 activity is tightly controlled, perhaps preventing the full induction of PLZF unless contact is maintained between developing DP cells, as may occur during the selection of iNKT and other hematopoietically selected T cells. This rapid dephosphorylation could provide a safety mechanism that allows only certain cells to develop and maintain high PLZF expression, and thereby limits the number of CD4+ T cells that develop innate-like characteristics.
However, whether Ly108 acts solely by potentiating TCR signaling and Egr-2 expression is not clear. Although the effects of Ly108 costimulation observed at the level of tyrosine phosphorylation and Ca2+ mobilization are subtle, these may affect duration of signals, which could lead to distinct outcomes in terms of gene expression and cell fate. However, the contrast with CD28 costimulation for the induction of PLZF expression suggests that the effects of Ly108 may go beyond that of boosting TCR signaling. The identification of distinct Ly108 signaling pathway(s) that contributes to PLZF expression therefore remains an important question.
Disclosures
The authors have no financial conflicts of interest.
Acknowledgments
We thank J. Reilley, R. Handon, and J. Fekecs (National Human Genome Research Institute, National Institutes of Health).
Footnotes
This work was supported by intramural funding of the National Human Genome Research Institute, National Institutes of Health (to P.L.S.), and National Institutes of Health Grants R01AI081314 (to D.L.W.) and AI045196 (to E.K.W.).
The online version of this article contains supplemental material.
Abbreviations used in this article:
- ChIP
- chromatin immunoprecipitation
- DN
- double negative
- DP
- double positive
- Egr
- early growth response protein
- iNKT
- invariant NKT
- LAT
- linker of activated T cells
- NS
- nonstimulated
- PKC
- protein kinase C
- PLC
- phospholipase C
- PLZF
- promyelocytic zinc finger transcription factor
- PS-DP
- preselection DP
- qRT-PCR
- quantitative RT-PCR
- SAP
- signaling lymphocyte activation molecule–associated protein
- SLAM
- signaling lymphocyte activation molecule
- SP
- single positive
- WT
- wild-type.
- Received August 2, 2012.
- Accepted December 27, 2012.